NASDAQ: MNMDMind Medicine Inc Stock
$5.77+0.31 (+5.68%)
Updated Apr 17, 2025
MNMD Price
$5.77
Fair Value Price
$0.36
Market Cap
$434.88M
52 Week Low
$4.70
52 Week High
$10.44
P/E
-3.75x
P/B
1.8x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$108.68M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
-$79M
Beta
1.69
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
MNMD Overview
Mind Medicine (MindMed) Incorporated develops products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. Its MM-120 offering is in a phase 2 clinical study for the treatment of generalized anxiety disorder, attention deficit hyperactivity disorder, and chronic pain. MM-110 is an a3ß4 nicotinic cholinergic receptor antagonist that has completed aphase 1 study for the treatment of opioid withdrawal. It is also developing MM-402, a treatment for core symptoms of autism spectrum disorder. MindMed is founded in 2002 and is headquartered in Vancouver, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MNMD's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MNMD
Ranked#340 of 463
Ranked#340 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important MNMD news, forecast changes, insider trades & much more!
MNMD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MNMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MNMD ($5.77) is overvalued by 1,514.06% relative to our estimate of its Fair Value price of $0.36 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MNMD ($5.77) is not significantly undervalued (1,514.06%) relative to our estimate of its Fair Value price of $0.36 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MNMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MNMD due diligence checks available for Premium users.
Valuation
MNMD fair value
Fair Value of MNMD stock based on Discounted Cash Flow (DCF)
Price
$5.77
Fair Value
$0.36
Overvalued by
1,514.06%
MNMD ($5.77) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MNMD ($5.77) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MNMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MNMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.75x
Industry
-177.72x
Market
27.98x
MNMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.8x
Industry
4.05x
MNMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MNMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$34.7M
Profit Margin
0%
MNMD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$302.2M
Liabilities
$60.7M
Debt to equity
0.25
MNMD's short-term assets ($281.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MNMD's short-term assets ($281.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MNMD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MNMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.4M
Investing
$0.0
Financing
$3.8M
MNMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MNMD vs Biotech Stocks
Mind Medicine Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.